Skip to main content Skip to navigation
Hamburger Menu
Search icon
Order lookup icon Order lookup icon
Order Lookup
Country Selector Country Selector
United States (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      Z-VAD-FMK, General Caspase Inhibitor
      Z-VAD-FMK, General Caspase Inhibitor
      Flow cytometric analysis of apoptosis in Jurkat cells (Human T-cell leukemia; ATCC TIB-152).  Jurkat cells were preincubated with the following: no inhibitor (upper left and bottom left panels), 20 µM Z-VAD-FMK (upper center and bottom center panels) or 20 µM negative control inhibitor (Z-FA-FMK, upper right and bottom right panels) (Cat. No. 550411) for 30 min, and then either left untreated (bottom row) or treated with 4 µM of campthothecin for 3 hr (top row). Following incubation, cells were collected and stained with PE Annexin V (Cat. No. 559763) to identify cells undergoing apoptosis. The results indicate that in campthothecin treated cells, approximately 42% of the cells were induced to undergo apoptosis and the use of the general caspase inhibitor Z-VAD-FMK reduced the level of apoptosis to that observed in the untreated control. Cells treated with Z-FA-FMK (Cat. No. 550411) showed similar results to the campthothecin treated cells without inhibitor, indicating that the negative control inhibitor did not attenuate apoptosis.
      Z-VAD-FMK, General Caspase Inhibitor
      Flow cytometric analysis of apoptosis in Jurkat cells (Human T-cell leukemia; ATCC TIB-152).  Jurkat cells were preincubated with the following: no inhibitor (upper left and bottom left panels), 20 µM Z-VAD-FMK (upper center and bottom center panels) or 20 µM negative control inhibitor (Z-FA-FMK, upper right and bottom right panels) (Cat. No. 550411) for 30 min, and then either left untreated (bottom row) or treated with 4 µM of campthothecin for 3 hr (top row). Following incubation, cells were collected and stained with PE Annexin V (Cat. No. 559763) to identify cells undergoing apoptosis. The results indicate that in campthothecin treated cells, approximately 42% of the cells were induced to undergo apoptosis and the use of the general caspase inhibitor Z-VAD-FMK reduced the level of apoptosis to that observed in the untreated control. Cells treated with Z-FA-FMK (Cat. No. 550411) showed similar results to the campthothecin treated cells without inhibitor, indicating that the negative control inhibitor did not attenuate apoptosis.
      Product Details
      Down Arrow Up Arrow


      BD Pharmingen™
      Flow cytometry (Routinely Tested)
      AB_2868880
      Lyophilized in dimethyl sulfoxide (DMSO).
      RUO


      Preparation And Storage

      Avoid multiple freeze-thaws of product.

      Store the lyophilized Z-VAD-FMK inhibitor at -20˚C. Reconstitute the Z-VAD-FMK inhibitor in DMSO before use. The reconstituted Z-VAD-FMK inhibitor may be stored in small aliquots at -20˚C.

      Show More blue down arrow Show Less blue up arrow

      Recommended Assay Procedures

      The Z-VAD-FMK inhibitor is designed to be used in both in vivo and in vitro cell based assays to measure the inhibition of apoptosis. Reconstitute 1.0 mg of the Z-VAD-FMK inhibitor in DMSO. A 10 mM stock solution may be made by dissolving 1.0 mg of Z-VAD-FMK in 214 µl DMSO. The final concentration of inhibitor may vary between experimental systems and investigators are encouraged to titrate the inhibitor for optimal performance. As a precautionary note, do not exceed a final DMSO concentration of 0.2% as higher levels may cause cellular toxicity and mask the effects of the caspase inhibitor.

      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
      2. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      Show More blue down arrow Show Less blue up arrow
      550377 Rev. 5
      Antibody Details
      Down Arrow Up Arrow

      Members of the caspase family play key roles in inflammation and mammalian apoptosis. Z-VAD-FMK is a cell permeable general caspase inhibitor that irreversibly binds to the catalytic site of caspase proteases and inhibits apoptosis. The peptide is O-methylated in the P1 position on aspartic acid providing enhanced stability and increased cell permeability. Z-VAD-FMK has a molecular weight of 467 Daltons.

      550377 Rev. 5
      Format Details
      Down Arrow Up Arrow
      Purified
      Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
      Purified
      550377 Rev.5
      Citations & References
      Down Arrow Up Arrow
      View product citations for antibody "550377" on CiteAb

      Development References (3)

      1. Gregoli PA, Bondurant MC. Function of caspases in regulating apoptosis caused by erythropoietin deprivation in erythroid progenitors. J Cell Physiol. 1999; 178(2):133-143. (Biology). View Reference
      2. Schrantz N, Blanchard DA, Auffredou MT, Sharma S, Leca G, Vazquez A. Role of caspases and possible involvement of retinoblastoma protein during TGFbeta-mediated apoptosis of human B lymphocytes. Oncogene. 1999; 18(23):3511-3519. (Biology). View Reference
      3. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998; 281(5381):1312-1316. (Biology). View Reference
      550377 Rev. 5

       

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.